April 27 (Reuters) - Theratechnologies Inc TH.TO :
* THERATECHNOLOGIES ANNOUNCES NEW POSITIVE RESULTS FOR TWO INVESTIGATIONAL PEPTIDE-DRUG CONJUGATES TARGETING SORTILIN POSITIVE OVARIAN CANCER
* THERATECHNOLOGIES - COMPARED TO TREATMENTS USING DOXORUBICIN OR DOCETAXEL, TH1902 AND TH1904 WERE BOTH FOUND TO HAVE BETTER EFFICACY
* THERATECHNOLOGIES INC - INTENDS TO INITIATE, BY END OF 2020, A FIRST-IN-HUMAN CLINICAL TRIAL WITH TH1902 IN CANCER PATIENTS